On June 17, the Food and Drug Administration announced a new national priority voucher plan. This initiative aims to reduce drug review times from the current average of 10 to 12 months to just one to two months.
Chrissy Buteas, president and chief executive officer of the HealthCare Institute of New Jersey, responded positively to this development on June 19. She stated, “Anything that can shorten a review period without compromising safety and efficacy means patients will benefit from new discoveries even sooner.”
